Table 1.
Demographic and clinicopathological characteristics of wide-margin, narrow-margin, and positive-margin plus stereotactic body radiotherapy (SBRT) groups.
| Variable | Wide-margin group | Narrow-margin group | P-Value | Positive-margin plus SBRT |
|---|---|---|---|---|
| (n = 134) | (n = 106) | (Wide vs. narrow) | (n = 9) | |
| Age ≤60 years old >60 years old |
87 (64.9%) 47 (35.1%) |
61 (57.5%) 45 (42.5%) |
0.243 | 6 (66.7%) 3 (33.3%) |
| Gender Male Female |
113 (84.3%) 21 (15.7%) |
95 (89.6%) 11 (10.4%) |
0.231 | 8 (88.9%) 1 (11.1%) |
| HBs Ag Positive Negative |
108 (80.6%) 26 (19.4%) |
75 (70.8%) 31 (29.2%) |
0.075 | 7 (77.8%) 2 (22.2%) |
| Cirrhosis Yes No |
100 (74.6%) 34 (25.4%) |
74 (69.8%) 32 (30.2%) |
0.407 | 9 (100.0%) 0 (0.0%) |
| Alcohol consumption Yes No |
75 (56.0%) 59 (44.0%) |
57 (53.8%) 49 (46.2%) |
0.734 | 1 (11.1%) 8 (88.9%) |
| AFP ≤20 ng/ml >20 ng/ml |
64 (47.8%) 70 (52.2%) |
39 (36.8%) 67 (63.2%) |
0.088 | 5 (55.6%) 4 (44.4%) |
| ALT ≤40 U/L >40 U/L |
94 (70.1%) 40 (29.9%) |
60 (56.6%) 46 (43.4%) |
0.030 | 6 (66.7%) 3 (33.3%) |
| TBIL ≤17.1umol/L >17.1umol/L |
87 (64.9%) 47 (35.1%) |
72 (67.9%) 34 (32.1%) |
0.626 | 5 (55.6%) 4 (44.4%) |
| ALB ≤35 g/L >35 g/L |
11 (8.2%) 123 (91.8%) |
11 (10.4%) 95 (89.6%) |
0.563 | 1 (11.1%) 8 (88.9%) |
| PT% <75 75-100 >100 |
0.189 | |||
| 9 (6.7%) | 6 (5.7%) | 1 (11.1%) | ||
| 96 (71.6%) | 66 (62.3%) | 4 (44.4%) | ||
| 29 (21.6%) | 34 (32.1%) | 4 (44.4%) | ||
| Child-Pugh class A5 A6 B7 |
0.377 | |||
| 123 (91.8%) | 93 (87.7%) | 8 (88.9%) | ||
| 10 (7.5%) | 10 (9.4%) | 0 (0.0%) | ||
| 1 (0.7%) | 3 (2.8%) | 1 (11.1%) | ||
| Tumor size ≤5 cm >5 cm |
89 (66.4%) 45 (33.6%) |
50 (47.2%) 56 (52.8%) |
0.003 | 5 (55.6%) 4 (44.4%) |
| No. of tumor Single Multiple |
119 (88.8%) 15 (11.2%) |
86 (81.1%) 20 (18.9%) |
0.094 | 8 (88.9%) 1 (11.1%) |
| Edmondson grades I-II III-IV |
104 (77.6%) 30 (22.4%) |
78 (73.6%) 28 (26.4%) |
0.469 | 5 (55.6%) 4 (44.4%) |
| Tumor capsule Present Absent |
115 (85.8%) 19 (14.2%) |
79 (74.5%) 27 (25.5%) |
0.027 | 3 (33.3%) 6 (66.7%) |
| MVI classification | 0.385 | |||
| M0 | 77 (57.5%) | 49 (46.2%) | 2 (22.2%) | |
| M1 | 37 (27.6%) | 36 (34.0%) | 4 (44.4%) | |
| M2 | 17 (12.7%) | 18 (17.0%) | 3 (33.3%) | |
| Unclear | 3 (2.2%) | 3 (2.8%) | 0 (0.0%) | |
| Extent of resection Minor Major |
88 (65.7%) 46 (34.3%) |
47 (44.3%) 59 (55.7%) |
<0.001 | 3 (33.3%) 6 (66.7%) |
| Operative time | 172.4 ± 72.0 | 224.9 ± 99.0 | <0.001 | 276.5 ± 83.6 |
| Operative blood loss | 276.2 ± 514.7 | 454.5 ± 608.7 | 0.019 | 210.0 ± 87.6 |
| pTNM stage I II* III IVA |
64 (47.8%) 52 (38.8%) 3 (2.2%) 15 (11.2%) |
30 (28.3%) 48 (45.3%) 7 (6.6%) 21 (19.8%) |
0.008 | 1 (11.1%) 7 (77.8%) 0 (0.0%) 1 (11.1%) |
| Postoperative TACE Yes No |
29 (21.6%) 105 (78.4%) |
28 (26.4%) 78 (73.6%) |
0.446 | 5 (55.6%) 4 (44.4%) |
Values in parentheses are percentages and P<0.05 was indicated by bold values.
HBs Ag, hepatitis B surface antigen; AFP, alpha-fetoprotein; ALT, alanine aminotransferase; TBIL, total bilirubin; ALB, albumin; PT, prothrombin time; MVI, microvascular invasion; pTNM stage, pathologic TNM stage; TACE, transcatheter arterial chemoembolization.
*5 cases that T stage (T1b or T2) was undefined because of unclear MVI status were belonged in category of T2 stage.